Trastuzumab

Metastatic Breast Cancer

Trastuzumab is indicated for the treatment of patients with HER2-positive metastatic breast cancer:

• as monotherapy (without other antitumor agents) for patients who have previously received one or more chemotherapy regimens for their metastatic disease
• in combination with paclitaxel or docetaxel for patients who have not yet received chemotherapy for their metastatic disease.
  
  Early Breast Cancer

Trastuzumab is indicated for the treatment of patients with HER2-positive early breast cancer:
• following surgery, chemotherapy (neoadjuvant or adjuvant), and radiotherapy (when applicable)

• after adjuvant chemotherapy with doxorubicin and cyclophosphamide, in combination with paclitaxel or docetaxel
  • in combination with adjuvant chemotherapy with docetaxel and carboplatin
  • in combination with neoadjuvant chemotherapy followed by adjuvant therapy with Ontruzant® for locally advanced (including inflammatory) breast cancer or tumors > 2 cm in diameter.
  
  

Advanced Gastric Cancer

Trastuzumab, in combination with capecitabine or intravenous 5-fluorouracil (5-FU) and a platinum agent, is indicated for the treatment of patients with HER2-positive, inoperable, locally advanced, recurrent, or metastatic adenocarcinoma of the stomach or gastroesophageal junction who have not received prior anticancer therapy for their metastatic disease.